Skip to main navigation menu Skip to main content Skip to site footer
DOI:
https://doi.org/10.57187/5375

Original article

Vol. 156 No. 11 (2026)

Autoimmune hepatitis is an independent risk factor for allograft loss and morbidity after liver transplantation: evidence from the Swiss Transplant Cohort Study

Cite this as:
Swiss Med Wkly. 2026;156:5375
Published
16.11.2026

Summary

BACKGROUND: Liver transplantation is the only curative option for end-stage autoimmune hepatitis (AIH). Although overall outcomes are favourable, previous studies suggest an increased risk of allograft loss and mortality in this population. We assessed post-liver transplantation outcomes in AIH recipients using data from the nationwide multicentre Swiss Transplant Cohort Study (STCS).

METHODS: We included all adult patients undergoing a first liver transplantation between May 2008 and December 2020. Indications were categorised as AIH, alcohol-related liver disease, viral liver disease, primary biliary cholangitis, primary sclerosing cholangitis, metabolic dysfunction-associated liver disease or other/mixed aetiologies. Survival analyses and multivariable competing risk Cox models were applied. Clinical Registration number (CER-VD): 2021-01982.

RESULTS: Among 880 liver transplantation recipients, 23 (2.6%) underwent liver transplantation for AIH. The 1-, 5- and 10-year post-liver transplantation survival rates in the AIH group were 87.0%, 76.5% and 76.5%, respectively – comparable to other indications. Allograft failure occurred in 34.8% of AIH recipients, significantly more often than in alcohol-related liver disease (8.3%, p <0.001), viral liver disease (13.5%, p = 0.003), primary sclerosing cholangitis (12.2%, p = 0.029) and metabolic dysfunction-associated liver disease (8.2%, p = 0.005). On multivariable analysis, AIH remained independently associated with increased allograft loss (HR 4.23, 95% CI 1.85–9.64; p = 0.003). Hepatic artery thrombosis occurred in 4/23 AIH patients and caused early allograft failure in all cases.

CONCLUSION: Despite comparable long-term survival, AIH recipients had a higher risk of early allograft loss, with vascular complications contributing to several early failures. Although the small AIH sample limited the precision of the estimated effects, these findings suggest the need for tailored pre- and post-transplant surveillance with particular attention to vascular complications.

References

  1. 1. Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. The Lancet. 2013 Oct;382(9902):1433-1444. doi:10.1016/S0140-6736(12)62163-1
  2. 2. Dalekos G, Gatselis N, Drenth JP, Heneghan M, Jørgensen M, Lohse AW, et al. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. Journal of Hepatology. 2025 Aug;83(2):453-501. doi:10.1016/j.jhep.2025.03.017
  3. 3. Hahn JW, Yang HR, Moon JS, Chang JY, Lee K, Kim GA, et al. Global incidence and prevalence of autoimmune hepatitis, 1970–2022: a systematic review and meta-analysis. eClinicalMedicine. 2023 Nov;65:102280. doi:10.1016/j.eclinm.2023.102280
  4. 4. Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmmune hepatitis. Cellular & Molecular Immunology. 2022 Feb;19(2):158-176. doi:10.1038/s41423-021-00768-8
  5. 5. González IA, Hartley CP, Nalbantoglu I. Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft. American Journal of Clinical Pathology. 2021 Feb 11;155(3):435-445. doi:10.1093/ajcp/aqaa147
  6. 6. Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). Journal of Hepatology. 2012 Sep;57(3):675-688. doi:10.1016/j.jhep.2012.04.015
  7. 7. Chouik Y, Chazouillères O, Francoz C, De Martin E, Guillaud O, Abergel A, et al. Long‐term outcome of liver transplantation for autoimmune hepatitis: A French nationwide study over 30 years. Liver International. 2023 May;43(5):1068-1079. doi:10.1111/liv.15552
  8. 8. Heinemann M, Adam R, Berenguer M, Mirza D, Malek‐Hosseini SA, O’Grady JG, et al. Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. Liver Transplantation. 2020 Jul;26(7):866-877. doi:10.1002/lt.25739
  9. 9. Lee JY, Danford CJ, Patwardhan VR, Bonder A. Increased Posttransplant Mortality for Autoimmune Hepatitis Compared With Other Autoimmune Liver Diseases. Journal of Clinical Gastroenterology. 2020 Aug;54(7):648-654. doi:10.1097/MCG.0000000000001271
  10. 10. Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Alimentary Pharmacology & Therapeutics. 2017 Feb;45(4):485-500. doi:10.1111/apt.13894
  11. 11. Edmunds C, Ekong UD. Autoimmune Liver Disease Post-Liver Transplantation. Transplantation. 2016 Mar;100(3):515-524. doi:10.1097/TP.0000000000000922
  12. 12. Czaja AJ. Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis After Liver Transplantation. Digestive Diseases and Sciences. 2012 Sep;57(9):2248-2266. doi:10.1007/s10620-012-2179-3
  13. 13. Montano-Loza AJ, Ronca V, Ebadi M, Hansen BE, Hirschfield G, Elwir S, et al. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology. 2022 Jul;77(1):84-97. doi:10.1016/j.jhep.2022.01.022
  14. 14. Montano-Loza AJ, Corpechot C, Burra P, Schramm C, Selzner N, Ronca V, et al. Recurrence of autoimmune liver diseases after liver transplantation: Review and expert opinion statement. Liver Transplantation. 2025 Mar;31(3):369-383. doi:10.1097/LVT.0000000000000419
  15. 15. Adam R, Karam V, Cailliez V, O Grady JG, Mirza D, Cherqui D, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transplant International. 2018 Dec;31(12):1293-1317. doi:10.1111/tri.13358
  16. 16. Robin F, Jasseron C, Legeai C, Kerbaul F, Giguet B, Houssel-Debry P, et al. Decision-making Tool for Early Liver Retransplantation: The Early Liver Retransplantation Score. Transplantation. 2026 Jan;110(1):e185-e196. doi:10.1097/TP.0000000000005476
  17. 17. Gwiasda J, Schrem H, Klempnauer J, Kaltenborn A. Identifying independent risk factors for graft loss after primary liver transplantation. Langenbeck's Archives of Surgery. 2017 Aug;402(5):757-766. doi:10.1007/s00423-017-1594-5
  18. 18. Lee BT, Tana MM, Kahn JA, Dara L. We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases. Hepatology. 2021 Nov;74(5):2876-2887. doi:10.1002/hep.31985
  19. 19. Westreich D, Greenland S. The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients. American Journal of Epidemiology. 2013 Feb 15;177(4):292-298. doi:10.1093/aje/kws412
  20. 20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology. 2008 Apr;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008
  21. 21. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020 Aug;72(2):671-722. doi:10.1002/hep.31065
  22. 22. Krishnamoorthy TL, Miezynska‐Kurtycz J, Hodson J, Gunson BK, Neuberger J, Milkiewicz P, et al. Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease. Liver Transplantation. 2016 Jan;22(1):34-41. doi:10.1002/lt.24323
  23. 23. Bekker J, Ploem S, De Jong KP. Early Hepatic Artery Thrombosis after Liver Transplantation: A Systematic Review of the Incidence, Outcome and Risk Factors. American Journal of Transplantation. 2009 Apr;9(4):746-757. doi:10.1111/j.1600-6143.2008.02541.x
  24. 24. Mourad MM, Liossis C, Gunson BK, Mergental H, Isaac J, Muiesan P, et al. Etiology and management of hepatic artery thrombosis after adult liver transplantation. Liver Transplantation. 2014 Jun;20(6):713-723. doi:10.1002/lt.23874
  25. 25. Khalaf H, Mourad W, El-Sheikh Y, Abdo A, Helmy A, Medhat Y, et al. Liver Transplantation for Autoimmune Hepatitis: A Single-Center Experience. Transplantation Proceedings. 2007 May;39(4):1166-1170. doi:10.1016/j.transproceed.2007.02.030
  26. 26. Pascual M, Thadhani R, Laposata M, Williams WW, Farrell ML, Johnson SM, et al. ANTICARDIOLIPIN ANTIBODIES AND HEPATIC ARTERY THROMBOSIS AFTER LIVER TRANSPLANTATION1,2. Transplantation. 1997 Nov;64(9):1361-1364. doi:10.1097/00007890-199711150-00021

Most read articles by the same author(s)

1 2 3 4 > >>